🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bristol
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Bristol

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca23 Eli Lilly and Company18 Merck Sharp & Dohme LLC17 Boehringer Ingelheim10 Janssen Research & Development, LLC9
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
269 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Exeter, Bournemouth, Bristol, Edinburgh, London, Sheffield, Swansea
2024-05-20
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Bristol, Cambridge, Dundee, Glasgow, Harrow, Hounslow, Leicester, Liverpool
2024-03-29
Active, closed
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934Ulcerative Colitis
Gilead Sciences
Phase 2
228
Bristol, Bury, Cambridge, Cardiff, London, North Shields
2024-03-27
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
Eli Lilly and Company
Phase 3
320
Bristol, Edinburgh, Glasgow, Nuneaton, Preston, Rochdale, Salford, Stevenage
2024-03-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Birmingham, Bristol, Liverpool, London, Manchester, Southampton
2024-03-14
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.
Phase 3
1,350
High Wycombe, Bristol, Glasgow, Hull, London, Oxford, Portsmouth, Preston
2024-03-13
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals
Phase 3
450
Bristol, Guildford, Coventry, London
2024-03-12
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Active, closed
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173Alzheimer Disease
Acumen Pharmaceuticals
Phase 2
542
London, Winchester, Motherwell, Preston, Guildford, Sheffield, Bristol
2024-02-29
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
Sanofi
Phase 3
464
Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool
2024-02-29
Recruiting
Hydrolysed Rice Formula Study
NCT06288503Cow's Milk Protein Allergy
Nutricia UK Ltd
Not applicable
86
Gloucester, Bristol
2024-02-01
Active, closed
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596Metastatic Urothelial Cancer
BicycleTx Limited
Phase 2
375
Bristol, Cambridge, London, Plymouth, Sutton
2024-01-24
Recruiting
Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access
NCT05846581Chronic Kidney Diseases, End Stage Renal Disease on Dialysis
W.L.Gore & Associates
Observational
72
Bristol
2024-01-12
Active, closed
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390Post-Bariatric Hypoglycemia
RECORDATI GROUP
Phase 2
93
Bristol, London
2024-01-04
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,020
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
Recruiting
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
NCT06259019Coronary Artery Disease
PlaqueTec Ltd
Not applicable
300
Bournemouth, Bristol, Cambridge, Norwich
2023-09-14
Rows per page Showing 126–150 of 269
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/bristol

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.